# Immunogenicity and Reactogenicity of the Beta-variant Recombinant Protein Booster Vaccine (VidPrevtyn Beta, Sanofi) Compared to a Bivalent mRNA Vaccine (Comirnaty Original/Omicron BA.4-5, BioNTech-Pfizer) in Adults Previously Vaccinated With at Least 3 Doses of COVID-19 mRNA Vaccine

> **NCT05749926** · PHASE3 · UNKNOWN · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 248 (actual)

## Conditions studied

- Vaccine Reaction
- COVID-19

## Interventions

- **BIOLOGICAL:** Comirnaty® BNT162b2 /Omicron BA.4-5 vaccine (Pfizer-BioNTech)
- **BIOLOGICAL:** VidPrevtyn® Beta vaccine (Sanofi/GSK)

## Key facts

- **NCT ID:** NCT05749926
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-05-16
- **Primary completion:** 2023-07-12
- **Final completion:** 2024-07-12
- **Target enrollment:** 248 (ACTUAL)
- **Last updated:** 2023-06-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05749926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05749926, "Immunogenicity and Reactogenicity of the Beta-variant Recombinant Protein Booster Vaccine (VidPrevtyn Beta, Sanofi) Compared to a Bivalent mRNA Vaccine (Comirnaty Original/Omicron BA.4-5, BioNTech-Pfizer) in Adults Previously Vaccinated With at Least 3 Doses of COVID-19 mRNA Vaccine". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05749926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*